Antibiotic dosing in critical illness

Journal of Antimicrobial Chemotherapy

Volumn 66, Issue SUPPL. 2, 2011, Pages

  McKenzie, Cathrine ^a,b  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b ST THOMAS HOSPITAL   (United Kingdom)

Author keywords

lactams; Aminoglycosides; Glycopeptides; ICUs; Pharmacodynamics

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; CARBAPENEM DERIVATIVE; CEFTAZIDIME; CEFTRIAXONE; CEFUROXIME; CEPHALOSPORIN DERIVATIVE; CIPROFLOXACIN; CLARITHROMYCIN; COLISTIN; DORIPENEM; FLUCLOXACILLIN; GENTAMICIN; MACROLIDE; MEROPENEM; METRONIDAZOLE; PENICILLIN DERIVATIVE; PENICILLIN G; PIPERACILLIN PLUS TAZOBACTAM; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TEICOPLANIN; TIGECYCLINE; VANCOMYCIN;

ANTIBIOTIC THERAPY; ARTICLE; BACTERICIDAL ACTIVITY; CONTINUOUS INFUSION; CRITICAL ILLNESS; CYSTIC FIBROSIS; DRUG EFFICACY; DRUG ELIMINATION; DRUG HYPERSENSITIVITY; DRUG METABOLISM; EXTRAVASCULAR SPACE; HUMAN; HYDROPHILICITY; INFECTION; INFLAMMATION; KIDNEY FAILURE; LIPOPHILICITY; LIVER FAILURE; MINIMUM INHIBITORY CONCENTRATION; NEPHROTOXICITY; NEUROTOXICITY; OBESITY; OTOTOXICITY; PATIENT SAFETY; SEPSIS; VASCULAR ACCESS;

ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; CRITICAL ILLNESS; HUMANS; TIME FACTORS;

EID: 79952612106     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkq516     Document Type: Article

References (49)

1. Dellinger RP, Levy MM, Carlet JM. et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med 2008; 36: 296-327.
2. Rivers E, Nguyen B, Havstad S. et al. Early Goal-Directed Therapy Collaborative Group. N Engl J Med 2001; 345: 1368-7.
3. NICE-SUGAR Study Investigators, Finfer S, Chittock DR. et al. Intensive versus conventional glucose control in critically ill patients. N Engl J Med 2009; 360: 1283-97.
4. Annane D, Bellissant E, Bollaert PE. et al. Corticosteroids for severe sepsis and septic shock: a systematic review and meta-analysis. BMJ 2004; 329: 480.
5. Bernard GR, Vincent JL, Laterre PF. et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001; 344: 699-709.
6. Kumar A, Roberts D, Wood KE. et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med 2006; 34: 1589.
7. Weatherall DJ, Ledingham JGG, Warrell DA. Oxford Textbook of Medicine. Oxford: Oxford University Press, 2000.
8. Erstad BL. Dosing of medications in morbidly obese patients in the intensive care unit setting. Intensive Care Med 2004; 30: 18-32.
9. Christoff J, Tolentino J, Mawdsley E. et al. Optimizing empirical antimicrobial therapy for infection due to Gram-negative pathogens in the intensive care unit: utility of a combination antibiogram. Infect Control Hosp Epidemiol 2010; 31: 256-61.
10. Moore R, Lietman P, Smith C. Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration. J Infect Dis 1987; 155: 93-9.
11. McEvoy G, Snow EK, Kester L. et al. AHFS Drug Information. Bethesda: American Society of Health System Pharmacists, 2008.
12. Pea F, Viale P. Bench-to-bedside review: appropriate antibiotic therapy in severe sepsis and septic shock-does the dose matter? Crit Care 2009;13 Suppl 1: P61.
13. Wheeler AP, Bernard GR. Treating patients with severe sepsis. N Engl J Med 1999; 340: 207-14.
14. Annane D, Bellissant E, Cavaillon JM. Septic shock. Lancet 2005; 365: 63-78.
15. Cheymol G. Clinical pharmacokinetics of drugs in obesity. An update. Clin Pharmacokinet 1993; 25: 103-14.
16. Hanley MJ, Abernethy DR, Greenblatt DJ. Effect of obesity on the pharmacokinetics of drugs in humans. Clin Pharmacokinet 2010; 49: 71-87.
17. Panidis D, Markantonis SL, Boutzouka E. et al. Penetration of gentamicin into the alveolar lining fluid of critically ill patients with ventilator-associated pneumonia. Chest 2005; 128: 545-52.
18. Reeves DS, MacGowan AP. Once-daily aminoglycoside dosing. Lancet 1993; 341: 895-6.
19. Panidis D, Markantonis SL, Boutzouka E. et al. Experience with a once-daily dosing program of aminoglycosides in critically ill patients. Intensive Care Med 2002; 28: 936-42.
20. Dollery C. Therapeutic Drugs. Edinburgh: Churchill Livingstone, 1991.
21. Barclay ML, Begg EJ, Hickling KG. What is the evidence for once-daily aminoglycoside therapy? Clin Pharmacokinet 1994; 27: 32-48.
22. Qian Y, Guan MX. Interaction of aminoglycosides with human mitochondrial 12S rRNA carrying the deafness-associated mutation. Antimicrob Agents Chemother 2009; 53: 4612-8.
23. Hyatt JM, McKinnon PS, Zimmer GS. et al. The importance of pharmacokinetic/pharmacodynamic surrogate markers to outcome. Focus on antibacterial agents. Clin Pharmacokinet 1995; 28: 143-60.
24. Li RC. New pharmacodynamic parameters for antimicrobial agents. Int J Antimicrob Agents 2000; 13: 229-35.
25. Li RC, Zhu M, Shentag JJ. Achieving an optimal outcome in the treatment of infections. The role of clinical pharmacokinetics and pharmacodynamics of antimicrobials. Clin Pharmacokinet 1999; 37: 1-16.
26. Conil JM, Georges B, Lussy A. et al. Ciprofloxacin use in critically ill patients: pharmacokinetic and pharmacodynamic approaches. Int J Antimicrob Agents 2008; 32: 505-10.
27. Falagas ME, Kasiakou SK, Tsiodras S. The use of intravenous and aerosolized polymxins for the treatment of in critically ill patients: a review of the recent literature. Clin Med Res 2006; 4: 138-46.
28. Ratjen F, Rietschel E, Kasel D. et al. Pharmacokinetics of inhaled colistin in patients with cystic fibrosis. J Antimicrob Chemother 2006; 57: 306-11.
29. Koch-Weser J, Sidel WW, Federman EB. et al. Adverse effects of sodium colistimethate. Manifestations and specific reaction rates during 317 courses of therapy. Ann Intern Med 1970; 72: 857-68.
30. Tallegran LG, Liewendhal K, Kuhlbeack B. The therapeutic success and nephrotoxicity of colistin in acute and chronic nephropathies with impaired renal function. Acta Med Scand 1965; 177: 717-28.
31. Roberts JA, Lipman J, Blot S. et al. Better outcomes through continuous infusions of time dependent antibiotics to critically ill patients. Curr Opin Crit Care 2008; 14: 390-6.
32. Lodise TP, Lomaestro BM, Drusano GL. Application of antimicrobial pharmacodynamic concepts into clinical practice: focus on beta-lactam antibiotics: insights from the Society of Infectious Diseases Pharmacists. Pharmacotherapy 2000; 26: 1320-32.
33. Roberts JA, Paratz JD, Lipman J. Continuous infusion of beta-lactams in the intensive care unit-best way to hit the target? Crit Care Med 2008; 36: 1663-4.
34. Nicolau DP, McNabb J, Lacy MK. et al. Continuous versus intermittent administration of ceftazidime in intensive care unit patients with nosocomial pneumonia. Int J Antimicrob Agents 2001; 17: 497-504.
35. Lorente L, Lorenzo L, Martin MM. et al. Meropenem by continuous versus intermittent infusion in ventilator associated pneumonia due to Gram-negative bacilli. Ann Pharmacother 2006; 40: 219-23.
36. Rybak M, Lomaestro B, Rotschafer JC. et al. Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm 2009; 66: 82-98.
37. Saunders NJ. Why monitor peak vancomycin concentrations? Lancet 1994; 344: 1748-50.
38. Wysocki M, Delatour F, Faurisson F. et al. Continuous versus intermittent infusion of vancomycin in severe staphylococcal infections: prospective multicenter randomized study. Antimicrob Agents Chemother 2001; 45: 2460-7.
39. Rello J, Sole-Violan J, Sa-Borges M. et al. Pneumonia caused by oxacillin resistant Staphylococcus aureus treated with glycopeptides. Crit Care Med 2005; 33: 1983-7.
40. Wyncoll DLA, Bowry R, Giles LJ. Antibiotics by continuous infusion: time for re-evaluation? In: Vincent JL, ed. Yearbook of Intensive Care Medicine. Berlin: Springer-Verlag, 2002; 398-406.
41. Park GR. Molecular mechanisms of drug metabolism in the critically ill. Br J Anaesth 1996; 77: 32-49.
42. Bodenham A, Shelly MP, Park GR. The altered pharmacokinetics and pharmacodynamics of drugs commonly used in critically ill patients. Clin Pharmacokinet 1988; 14: 347-73.
43. Rea RS, Capitano B. Optimizing use of aminoglycosides in the critically ill. Semin Respir Crit Care Med 2007; 28: 596-603.
44. Ronco C, Bellomo R, Kellum JA. Continuous renal replacement therapy: opinions and evidence. Adv Ren Replace Ther 2002; 9: 229-44.
45. Davies JG, Kingswood JC, Sharpstone P. et al. Drug removal in continuous haemofiltration and haemodialysis. Br J Hosp Med 1991; 54: 524-8.
46. Bouman CS. Antimicrobial dosing strategies in critically ill patients with acute kidney injury and high-dose continuous veno-venous hemofiltration. Curr Opin Crit Care 2008; 14: 654-9.
47. Ashley C, Currie A. The Renal Drug Handbook. Oxford: Radcliffe Publishing, 2009.
48. Rifampicin: Summary of Product Characteristics. http://www.medicines.org.uk/EMC/medicine/6435/SPC/Rifadin+For+Infusion+600mg/ (21 May 2010, date last accessed).
49. Hatton K, Barrett N, Lim J. et al. Allergy documentation and transfer within critical care. Crit Care 2010; 14 Suppl 1: P451.